Zoetis Inc. $ZTS Shares Acquired by Aptus Capital Advisors LLC

Key Points

• Aptus Capital Advisors LLC increased its stake in Zoetis Inc. by 96.6% during the first quarter, owning a total of 13,062 shares valued at approximately $2.15 million.
• Multiple institutional investors, including Tandem Investment Advisors Inc. and Portside Wealth Group LLC, have also significantly increased their holdings in Zoetis.
• Zoetis reported $1.76 EPS for the last quarter, exceeding analyst estimates, and set its FY 2025 guidance at 6.300-6.400 EPS.

Aptus Capital Advisors LLC increased its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 96.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,062 shares of the company's stock after purchasing an additional 6,419 shares during the period. Aptus Capital Advisors LLC's holdings in Zoetis were worth $2,151,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Navigoe LLC purchased a new stake in shares of Zoetis in the fourth quarter valued at $30,000. Cornerstone Planning Group LLC boosted its holdings in Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after acquiring an additional 88 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in Zoetis by 87.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock valued at $42,000 after acquiring an additional 120 shares during the last quarter. Sound Income Strategies LLC boosted its holdings in Zoetis by 141.4% in the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after acquiring an additional 164 shares during the last quarter. Finally, Bfsg LLC boosted its holdings in Zoetis by 614.6% in the first quarter. Bfsg LLC now owns 293 shares of the company's stock valued at $48,000 after acquiring an additional 252 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Stock Up 0.5%

Shares of ZTS traded up $0.7080 during midday trading on Friday, reaching $156.3180. 2,426,297 shares of the company were exchanged, compared to its average volume of 3,495,215. The stock has a 50-day moving average price of $153.84 and a 200-day moving average price of $158.52. The company has a market cap of $69.28 billion, a price-to-earnings ratio of 26.91, a P/E/G ratio of 2.51 and a beta of 0.88. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. The company had revenue of $2.46 billion for the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm's quarterly revenue was up 4.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the transaction, the executive vice president owned 15,129 shares in the company, valued at $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.18% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and reduced their target price for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Piper Sandler lifted their target price on Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and reduced their target price for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Finally, UBS Group reduced their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Zoetis has an average rating of "Moderate Buy" and a consensus price target of $202.43.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.